Commercial With oral obesity race underway, all eyes are on Lilly’s Foundayo launch BioSpaceNovo Nordisk's oral Wegovy has a few months' head start on Eli Lilly's newly approved pill.CommercialMetabolic & GLP-1Read full story pharminent April 10, 2026 (Last updated: April 10, 2026) BioSpace Novo Nordisk’s oral Wegovy has a few months’ head start on Eli Lilly’s newly approved pill. CommercialMetabolic & GLP-1Read full story Post navigation Previous: Senju launches first-in-class dry eye disease drug in JapanNext: RFK Jr. rewrites ACIP rules; Gilead, Roche dig into protein degraders Related Stories Commercial Novo’s CEO champions “record-breaking start” for Wegovy pill in US market pharminent May 8, 2026 Commercial Novo hikes guidance on Wegovy pill’s fast sales start pharminent May 6, 2026 Commercial Novo’s Wegovy pill reaches 1M patients, shattering expectations with $355M in sales pharminent May 6, 2026
